Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05353530 · ClinicalTrials.gov registry record · Phase 1
IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma
A Phase 1 study of Glioblastoma and Glioblastoma Multiforme, sponsored by University of Florida.
- Active
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT05353530 is a Phase 1 study of Glioblastoma and Glioblastoma Multiforme that is active but no longer recruiting, run by University of Florida. The registered enrollment target is 39 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05353530, a Phase 1 study of Glioblastoma and Glioblastoma Multiforme, is active but no longer recruiting, sponsored by University of Florida.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase I study to assess the safety and feasibility of IL-8 receptor modified patient-derived activated CD70 CAR T cell therapy in CD70+ adult glioblastoma
Conditions Studied
Interventions
- BIOLOGICAL Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells
Study Locations (1)
Florida
- University of Florida Health - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2023-07-25 |
| Est. Completion | 2042-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05353530
The ClinicalTrials.gov registry entry for NCT05353530 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (64% lower). The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells is the first listed.
NCT05353530 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT05353530 about?
NCT05353530 is a clinical study titled "IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma". This is a phase I study to assess the safety and feasibility of IL-8 receptor modified patient-derived activated CD70 CAR T cell therapy in CD70+ adult glioblastoma
What is the current status of trial NCT05353530?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2023-07-25. Estimated completion is 2042-12.
What conditions does trial NCT05353530 study?
This clinical trial studies the following conditions: Glioblastoma, Glioblastoma Multiforme.
What interventions are being tested in trial NCT05353530?
The interventions under investigation include: Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT05353530?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05353530 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
RECRUITING · Phase 1
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.